[Hypercholesterolemia - Where are we today? Where are we going?]

Area of Science:

• Cardiology
• Metabolic Disorders
• Pharmacology

Background:

• Hypercholesterolemia is a key modifiable risk factor for atherosclerosis and cardiovascular disease.
• Elevated LDL cholesterol levels significantly increase the risk of cardiovascular ischemic events.
• Current guidelines recommend strict LDL cholesterol goals (<70 mg/dL) for high-risk individuals.

Purpose of the Study:

• To evaluate the effectiveness of current lipid-lowering strategies in achieving guideline-recommended LDL cholesterol goals.
• To identify barriers to goal attainment in high-risk patient populations.
• To discuss potential therapeutic advancements for optimizing LDL cholesterol reduction.

Main Methods:

• Analysis of data from randomized trials and observational studies on lipid-lowering therapies.
• Review of current clinical practice guidelines for hypercholesterolemia management.
• Assessment of treatment patterns and goal achievement rates in high-risk patients.

Main Results:

• Only approximately 20% of treated high-risk patients achieve the recommended LDL cholesterol goal in routine clinical practice.
• Many high-risk patients are undertreated, often receiving low to moderate statin dosages.
• Significant gaps exist between guideline recommendations and real-world LDL cholesterol management.

Conclusions:

• Current therapeutic approaches are insufficient for achieving target LDL cholesterol levels in a majority of high-risk patients.
• Intensified lipid-lowering strategies, including high-dose statins, statin-ezetimibe combination therapy, and novel agents like PCSK9 inhibitors, are necessary.
• Improved adherence to guidelines and enhanced cardiac rehabilitation programs are crucial for reducing cardiovascular risk.